Movatterモバイル変換


[0]ホーム

URL:


SG10201504971QA - Mice that make binding proteins comprising vl domains - Google Patents

Mice that make binding proteins comprising vl domains

Info

Publication number
SG10201504971QA
SG10201504971QASG10201504971QASG10201504971QASG10201504971QASG 10201504971Q ASG10201504971Q ASG 10201504971QASG 10201504971Q ASG10201504971Q ASG 10201504971QASG 10201504971Q ASG10201504971Q ASG 10201504971QASG 10201504971Q ASG10201504971Q ASG 10201504971QA
Authority
SG
Singapore
Prior art keywords
domains
mice
binding proteins
make binding
make
Prior art date
Application number
SG10201504971QA
Inventor
Lynn Macdonald
Sean Stevens
Cagan Gurer
Karolina A Hosiawa
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=44543797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201504971Q(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron PharmafiledCriticalRegeneron Pharma
Publication of SG10201504971QApublicationCriticalpatent/SG10201504971QA/en

Links

Classifications

Landscapes

SG10201504971QA2010-08-022011-08-02Mice that make binding proteins comprising vl domainsSG10201504971QA (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US36990910P2010-08-022010-08-02

Publications (1)

Publication NumberPublication Date
SG10201504971QAtrue SG10201504971QA (en)2015-07-30

Family

ID=44543797

Family Applications (3)

Application NumberTitlePriority DateFiling Date
SG10201504971QASG10201504971QA (en)2010-08-022011-08-02Mice that make binding proteins comprising vl domains
SG2013007893ASG187673A1 (en)2010-08-022011-08-02Mice that make binding proteins comprising vl domains
SG10201912639SASG10201912639SA (en)2010-08-022011-08-02Mice that make binding proteins comprising vl domains

Family Applications After (2)

Application NumberTitlePriority DateFiling Date
SG2013007893ASG187673A1 (en)2010-08-022011-08-02Mice that make binding proteins comprising vl domains
SG10201912639SASG10201912639SA (en)2010-08-022011-08-02Mice that make binding proteins comprising vl domains

Country Status (27)

CountryLink
US (7)US9516868B2 (en)
EP (3)EP3960865A1 (en)
JP (6)JP6146913B2 (en)
KR (4)KR102008655B1 (en)
CN (4)CN113150121B9 (en)
AU (1)AU2011285919C1 (en)
BR (1)BR112013002695B1 (en)
CA (1)CA2807282A1 (en)
CY (1)CY1118562T1 (en)
DK (1)DK2601298T3 (en)
ES (1)ES2612459T3 (en)
HK (1)HK1217511A1 (en)
HR (1)HRP20170322T1 (en)
HU (1)HUE031903T2 (en)
IL (4)IL315833A (en)
LT (1)LT2601298T (en)
MX (5)MX2018014787A (en)
MY (1)MY172618A (en)
NZ (2)NZ707327A (en)
PL (1)PL2601298T3 (en)
PT (1)PT2601298T (en)
RS (1)RS55495B1 (en)
RU (2)RU2750219C2 (en)
SG (3)SG10201504971QA (en)
SI (1)SI2601298T1 (en)
SM (2)SMT201700023T1 (en)
WO (1)WO2012018764A1 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2009143472A2 (en)*2008-05-232009-11-26Aliva Biopharmaceuticals, Inc.Method of generating single vl domain antibodies in transgenic animals
US9445581B2 (en)2012-03-282016-09-20Kymab LimitedAnimal models and therapeutic molecules
PT2564695E (en)2009-07-082015-06-03Kymab LtdAnimal models and therapeutic molecules
US20130045492A1 (en)2010-02-082013-02-21Regeneron Pharmaceuticals, Inc.Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en)2010-02-082017-10-24Regeneron Pharmaceuticals, Inc.Mice expressing a limited immunoglobulin light chain repertoire
PT2505654T (en)2010-02-082016-11-18Regeneron Pharma COMMON LIGHT CHAIN MOUSE
KR20130097156A (en)2010-07-262013-09-02트리아니, 인코포레이티드Transgenic animals and methods of use
US10662256B2 (en)2010-07-262020-05-26Trianni, Inc.Transgenic mammals and methods of use thereof
US10793829B2 (en)2010-07-262020-10-06Trianni, Inc.Transgenic mammals and methods of use thereof
ES2612459T3 (en)2010-08-022017-05-17Regeneron Pharmaceuticals, Inc. Mice that produce binding proteins that comprise VL domains
FI3865581T3 (en)2011-08-052024-11-02Regeneron Pharma Humanized universal light chain mice
EP3741862A1 (en)2011-09-192020-11-25Kymab LimitedAnimals, repertoires & methods for the production of human antibodies
EP2757875B2 (en)*2011-09-192023-03-22Kymab LimitedManipulation of immunoglobulin gene diversity and multi-antibody therapeutics
WO2013045916A1 (en)2011-09-262013-04-04Kymab LimitedChimaeric surrogate light chains (slc) comprising human vpreb
LT3216871T (en)2011-10-172022-03-25Regeneron Pharmaceuticals, Inc.Restricted immunoglobulin heavy chain mice
US9253965B2 (en)2012-03-282016-02-09Kymab LimitedAnimal models and therapeutic molecules
BR122021007339B1 (en)2011-12-202022-11-29Regeneron Pharmaceuticals, Inc A METHOD FOR PREPARING A NON-HUMAN ANIMAL, COMPRISING GENETIC MODIFYING AN EX VIVO NON-HUMAN ANIMAL CELL MODIFIED BY PLACING AN ADAM6 GENE, AND, EX VIVO USES OF THE CELL OR TISSUE DERIVED FROM THE NON-HUMAN ANIMAL
RU2770016C2 (en)*2012-02-012022-04-14Регенерон Фармасьютикалз, Инк.Humanized rodents which express heavy chains containing vl domains
WO2013134880A1 (en)*2012-03-142013-09-19Innovative Targeting Solutions Inc.Generating targeted sequence diversity in proteins
EP2825653A4 (en)2012-03-142016-01-20Innovative Targeting Solutions IncGenerating targeted sequence diversity in fusion proteins
GB2502127A (en)2012-05-172013-11-20Kymab LtdMultivalent antibodies and in vivo methods for their production
US10251377B2 (en)2012-03-282019-04-09Kymab LimitedTransgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
PT3597037T (en)2012-06-122021-06-01Regeneron PharmaHumanized non-human animals with restricted immunoglobulin heavy chain loci
WO2014022540A1 (en)2012-08-022014-02-06Regeneron Pharmaceuticals, Inc.Multivalent antigen-binding proteins
HRP20181151T1 (en)*2013-02-202018-09-21Regeneron Pharmaceuticals, Inc.Non-human animals with modified immunoglobulin heavy chain sequences
TR201901668T4 (en)*2013-03-132019-02-21Regeneron Pharma Mice expressing a limited immunoglobulin light chain repertoire.
MY183572A (en)2013-03-152021-02-26Regeneron PharmaBiologically active molecules, conjugates thereof, and therapeutic uses
US9788534B2 (en)2013-03-182017-10-17Kymab LimitedAnimal models and therapeutic molecules
US9783618B2 (en)2013-05-012017-10-10Kymab LimitedManipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en)2013-05-022017-10-10Kymab LimitedAntibodies, variable domains and chains tailored for human use
US11707056B2 (en)2013-05-022023-07-25Kymab LimitedAnimals, repertoires and methods
EA038192B1 (en)2013-08-262021-07-21Регенерон Фармасьютикалз, Инк.Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
CA2925723A1 (en)2013-10-012015-04-09Kymab LimitedAnimal models and therapeutic molecules
FR3011249A1 (en)*2013-10-012015-04-03Kymab Ltd
WO2015143414A2 (en)*2014-03-212015-09-24Regeneron Pharmaceuticals, Inc.Non-human animals that make single domain binding proteins
HK1231497A1 (en)*2014-03-212017-12-22瑞泽恩制药公司Vl antigen binding proteins exhibiting distinct binding characteristics
JP2018508224A (en)*2015-03-192018-03-29リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Non-human animals that select light chain variable regions that bind antigen
KR102708103B1 (en)2015-03-272024-09-20리제너론 파아마슈티컬스, 인크. Maytansinoid derivatives, conjugates thereof, and methods of use
EP3303386B1 (en)2015-06-052024-08-28Genentech, Inc.Anti-tau antibodies and methods of use
WO2017095939A1 (en)2015-12-032017-06-08Trianni, Inc.Enhanced immunoglobulin diversity
AU2017211120C1 (en)2016-01-252021-10-07Regeneron Pharmaceuticals, Inc.Maytansinoid derivatives, conjugates thereof, and methods of use
IL260743B2 (en)2016-02-042024-03-01Trianni IncEnhanced production of immunoglobulins
KR102356542B1 (en)2016-05-202022-01-28리제너론 파마슈티칼스 인코포레이티드 A method for disrupting immunological resistance using multiple guide RNAs
US10980221B2 (en)2016-06-032021-04-20Regeneron Pharmaceuticals, Inc.Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
WO2018089373A2 (en)2016-11-082018-05-17Regeneron Pharmaceuticals, Inc.Steroids and protein-conjugates thereof
EP3551655A2 (en)2016-12-072019-10-16Genentech, Inc.Anti-tau antibodies and methods of their use
TW202328181A (en)2016-12-072023-07-16美商建南德克公司Anti-tau antibodies and methods of use
JP2020505037A (en)*2017-01-192020-02-20オープン モノクローナル テクノロジー,インコーポレイテッド Human antibodies from transgenic rodents having multiple heavy chain immunoglobulin loci
CA3063871A1 (en)2017-05-182018-11-22Regeneron Pharmaceuticals, Inc.Cyclodextrin protein drug conjugates
WO2019051164A1 (en)2017-09-072019-03-14Augusta University Research Institute, Inc.Antibodies to programmed cell death protein 1
IL274427B2 (en)2017-11-072024-11-01Regeneron Pharma Hydrophilic linkers for drug-antibody conjugates
CA3086926A1 (en)2018-01-082019-07-11Regeneron Pharmaceuticals, Inc.Steroids and antibody-conjugates thereof
KR102862947B1 (en)2018-03-242025-09-24리제너론 파마슈티칼스 인코포레이티드 Genetically modified non-human animals for producing therapeutic antibodies against peptide-MHC complexes, and methods for producing the same
SG11202008620VA (en)2018-03-262020-10-29Regeneron PharmaHumanized rodents for testing therapeutic agents
CA3098453A1 (en)2018-05-092019-11-14Regeneron Pharmaceuticals, Inc.Anti-msr1 antibodies and methods of use thereof
IL318469A (en)2018-06-142025-03-01Regeneron PharmaNon-human animals capable of engineered dh-dh rearrangement and uses thereof
JP2020146316A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146313A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146298A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146317A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146309A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146306A (en)*2019-03-142020-09-17株式会社三洋物産 Game machine
JP2020146314A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146305A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146307A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146302A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146299A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146297A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146308A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146301A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146304A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146312A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146303A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146315A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146300A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146310A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2020146318A (en)*2019-03-142020-09-17株式会社三洋物産Game machine
JP2023521885A (en)2020-04-162023-05-25リジェネロン・ファーマシューティカルズ・インコーポレイテッド Diels-Alder conjugation method
MX2023000544A (en)2020-07-132023-02-13Regeneron PharmaCamptothecin analogs conjugated to a glutamine residue in a protein, and their use.
EP4211155A1 (en)2020-09-112023-07-19Regeneron Pharmaceuticals, Inc.Identification and production of antigen-specific antibodies
WO2022056494A1 (en)2020-09-142022-03-17Regeneron Pharmaceuticals, Inc.Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
JP2024500399A (en)2020-12-162024-01-09リジェネロン・ファーマシューティカルズ・インコーポレイテッド Mice expressing humanized Fc alpha receptors
US20240317849A1 (en)2020-12-232024-09-26Regeneron Pharmaceuticals, Inc.Nucleic acids encoding anchor modified antibodies and uses thereof
US20230287138A1 (en)2022-01-122023-09-14Regneron Pharmaceuticals, Inc.Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
WO2023147470A2 (en)2022-01-282023-08-03Georgiamune Inc.Antibodies to programmed cell death protein 1 that are pd-1 agonists
AU2023407365A1 (en)2022-12-212025-07-31Regeneron Pharmaceuticals, Inc.Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
WO2025096921A1 (en)2023-11-032025-05-08Regeneron Pharmaceuticals, Inc.Peptide acids as a glp1r agonist and antibody-drug conjugates thereof

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4977081A (en)1987-05-041990-12-11Adi Diagnostics, Inc.Stable rabbit-mouse hybridomas and secretion products thereof
GB8823869D0 (en)1988-10-121988-11-16Medical Res CouncilProduction of antibodies
US5075181A (en)1989-05-051991-12-24Kennametal Inc.High hardness/high compressive stress multilayer coated tool
WO1991000906A1 (en)1989-07-121991-01-24Genetics Institute, Inc.Chimeric and transgenic animals capable of producing human antibodies
DK0463151T3 (en)1990-01-121996-07-01Cell Genesys Inc Generation of xenogenic antibodies
US6657103B1 (en)1990-01-122003-12-02Abgenix, Inc.Human antibodies derived from immunized xenomice
US6075181A (en)1990-01-122000-06-13Abgenix, Inc.Human antibodies derived from immunized xenomice
US6150584A (en)1990-01-122000-11-21Abgenix, Inc.Human antibodies derived from immunized xenomice
US6673986B1 (en)1990-01-122004-01-06Abgenix, Inc.Generation of xenogeneic antibodies
CA2066433A1 (en)1990-07-101992-01-11Haruo MatsudaChicken-specific immunoglobulin g-producing hybridoma
US6255458B1 (en)1990-08-292001-07-03Genpharm InternationalHigh affinity human antibodies and human antibodies against digoxin
US5770429A (en)*1990-08-291998-06-23Genpharm International, Inc.Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en)1995-10-102006-05-09Genpharm International, Inc.Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)1990-08-291996-08-13Genpharm International, Inc.Ransgenic non-human animals for producing heterologous antibodies
JP2835787B2 (en)1991-03-221998-12-14キヤノン株式会社 Ferroelectric liquid crystal device
AU669124B2 (en)1991-09-181996-05-30Kyowa Hakko Kirin Co., Ltd.Process for producing humanized chimera antibody
US5150584A (en)1991-09-261992-09-29General Motors CorporationMethod and apparatus for detecting low refrigerant charge
EP0583980A1 (en)1992-08-201994-02-23Eli Lilly And CompanyMethod for generating monoclonal antibodies from rabbits
US6765087B1 (en)1992-08-212004-07-20Vrije Universiteit BrusselImmunoglobulins devoid of light chains
US6005079A (en)1992-08-211999-12-21Vrije Universiteit BrusselsImmunoglobulins devoid of light chains
ATE452975T1 (en)1992-08-212010-01-15Univ Bruxelles IMMUNOGLOBULINS WITHOUT LIGHT CHAINS
FI952658A0 (en)1992-12-011995-05-31Protein Design Labs Inc With L-selectin reactive humanized antibodies
DE4309308C1 (en)1993-03-231994-04-14Siemens Nixdorf Inf SystVentilation system for power electronic appts. housing - has 2 overlying ventilation units inserted between upper and lower halves of function module stack.
IL109168A0 (en)*1993-04-011994-06-24Univ ColumbiaA retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
JPH08509612A (en)1993-04-261996-10-15ジェンファーム インターナショナル インコーポレイテッド Transgenic non-human animal capable of producing heterologous antibody
US5523226A (en)1993-05-141996-06-04Biotechnology Research And Development Corp.Transgenic swine compositions and methods
EP0739981A1 (en)1995-04-251996-10-30Vrije Universiteit BrusselVariable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6632976B1 (en)1995-08-292003-10-14Kirin Beer Kabushiki KaishaChimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
AU7326796A (en)1995-10-301997-05-22Spectral Diagnostics Inc.Stable chicken b-cell line and method of use thereof
AU3507297A (en)1996-06-261998-01-14Baylor College Of MedicineChromosomal rearrangement by insertion of two recombination substrates
KR100643058B1 (en)1996-12-032006-11-13아브게닉스, 인크.Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
CN1203922A (en)1997-03-211999-01-06三共株式会社Humanized anti-human fas antibody
US20020062010A1 (en)1997-05-022002-05-23Genentech, Inc.Method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en)1997-05-302004-08-10Carnegie Institution Of WashingtonUse of FLP recombinase in mice
GB9823930D0 (en)1998-11-031998-12-30Babraham InstMurine expression of human ig\ locus
JP2003501016A (en)1999-05-272003-01-14ヒューマン ジノーム サイエンシーズ, インコーポレイテッド ADAM polynucleotides and polypeptides
GB0001448D0 (en)2000-01-212000-03-08Novartis AgOrganic compounds
AU8470301A (en)*2000-08-032002-02-18Wim-Van SchootenProduction of humanized antibodies in transgenic animals
US6596541B2 (en)2000-10-312003-07-22Regeneron Pharmaceuticals, Inc.Methods of modifying eukaryotic cells
US6586251B2 (en)2000-10-312003-07-01Regeneron Pharmaceuticals, Inc.Methods of modifying eukaryotic cells
US7105348B2 (en)2000-10-312006-09-12Regeneron Pharmaceuticals, Inc.Methods of modifying eukaryotic cells
PE20020574A1 (en)2000-12-062002-07-02Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
GB0110029D0 (en)2001-04-242001-06-13Grosveld FrankTransgenic animal
US7034134B2 (en)2001-04-262006-04-25Bristol-Myers Squibb CompanyPolynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
CA2446968C (en)2001-05-112012-07-03Kirin Beer Kabushiki KaishaHuman artificial chromosome containing human antibody .lambda. light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission
GB0115256D0 (en)2001-06-212001-08-15Babraham InstMouse light chain locus
EP1399484B1 (en)2001-06-282010-08-11Domantis LimitedDual-specific ligand and its use
FR2827302B1 (en)*2001-07-132003-10-10Genoway TRANSGENIC CELL AND ANIMAL MODELING HUMAN ANTIGENIC PRESENTATION AND USES THEREOF
US20030108925A1 (en)2001-10-052003-06-12U.S. EpaGenetic testing for male factor infertility
US20060199204A1 (en)2001-10-052006-09-07U.S. EpaGenetic testing for male factor infertility
CA2847885C (en)*2001-11-302022-03-22Amgen Fremont Inc.Transgenic animals bearing human ig.lambda. light chain genes
EP1461423B1 (en)2001-12-032008-05-14Amgen Fremont Inc.Antibody categorization based on binding characteristics
AU2003230741A1 (en)2002-03-222003-10-13Origen TherapeuticsTransgenic aves producing human polyclonal antibodies
ATE328906T1 (en)2002-06-282006-06-15Domantis Ltd DUAL-SPECIFIC LIGANDS WITH INCREASED HALF-LIFE
FI117110B (en)2002-07-052006-06-15Outokumpu Oy Feeding an anode into a melting reactor
CA2872136C (en)2002-07-182017-06-20Merus B.V.Recombinant production of mixtures of antibodies
US20040101920A1 (en)2002-11-012004-05-27Czeslaw RadziejewskiModification assisted profiling (MAP) methodology
GB0228210D0 (en)*2002-12-032003-01-08Babraham InstSingle chain antibodies
GB0230203D0 (en)*2002-12-272003-02-05Domantis LtdFc fusion
GB0230201D0 (en)2002-12-272003-02-05Domantis LtdRetargeting
JP2006523090A (en)2002-12-272006-10-12ドマンティス リミテッド Bispecific single domain antibody specific for ligand and for ligand receptor
GB2398784B (en)2003-02-262005-07-27Babraham InstRemoval and modification of the immunoglobulin constant region gene cluster of a non-human mammal
US20100069614A1 (en)*2008-06-272010-03-18Merus B.V.Antibody producing non-human mammals
EP2395016A3 (en)*2003-05-302012-12-19Merus B.V.Design and use of paired variable regions of specific binding molecules
WO2005001087A2 (en)2003-06-112005-01-06Regeneron Pharmaceuticals, Inc.Methods of modifying genes in eukaryotic cells
CN103205436B (en)2003-07-152016-05-25人类多克隆治疗公司humanized immunoglobulin loci
WO2005019463A1 (en)2003-08-112005-03-03Therapeutic Human Polyclonals, Inc.Improved transgenesis with humanized immunoglobulin loci
RU2251699C1 (en)2003-09-252005-05-10Киселев Всеволод ИвановичMethod for early and preclinical diagnostics of cervical cancer
WO2005038001A2 (en)2003-10-142005-04-28Therapeutic Human Polyclonals, Inc.Improved transgenesis by sperm-mediated gene transfer
FR2861255B1 (en)2003-10-242006-02-17Centre Nat Rech Scient NON-HUMAN TRANSGENIC MAMMAL FOR THE CONSTANT REGION OF THE HEAVY CHAIN OF HUMAN CLASS A IMMUNOGLOBULINS AND ITS APPLICATIONS
ES2523661T3 (en)*2004-07-222014-11-28Erasmus University Medical Center Rotterdam Binding molecules
AU2005295269B2 (en)2004-10-192010-05-13Regeneron Pharmaceuticals, Inc.Method for generating an animal homozygous for a genetic modification
CA2584814A1 (en)2004-10-222006-05-04Therapeutic Human Polyclonals, Inc.Suppression of endogenous immunoglobulin expression in non-human transgenic animals
BRPI0706750A2 (en)2006-01-252011-04-05Univ Erasmus Medical Ct heavy chain antibody generation in transgenic animals
GB0618345D0 (en)*2006-09-182006-10-25Univ ErasmusBinding molecules
EP2505058A1 (en)2006-03-312012-10-03Medarex, Inc.Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
AU2007254831B2 (en)2006-06-022012-03-22Regeneron Pharmaceuticals, Inc.High affinity antibodies to human IL-6 receptor
JP5087625B2 (en)2006-09-012012-12-05セラピューティック・ヒューマン・ポリクローナルズ・インコーポレーテッド Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
UA98943C2 (en)*2006-10-022012-07-10Ридженерон Фармасьютикалз, Инк.High affinity human antibodies to human il-4 receptor
RU2448979C2 (en)2006-12-142012-04-27Ридженерон Фармасьютикалз, Инк.Human antibodies to delta-like human ligand-4
ES2664218T3 (en)2007-06-012018-04-18Open Monoclonal Technology, Inc Compositions and methods of inhibiting endogenous immunoglobulin genes and producing transgenic human idiotypic antibodies
WO2009013620A2 (en)2007-06-112009-01-29Erasmus University Medical Center RotterdamHomologous recombination
ITMI20071522A1 (en)2007-07-272009-01-28Areta Internat S R L IDIOTYPIC VACCINE
AU2008282218A1 (en)*2007-07-312009-02-05Medimmune, LlcMultispecific epitope binding proteins and uses thereof
WO2009097006A2 (en)2007-08-102009-08-06Medarex, Inc.Hco32 and hco27 and related examples
US8426565B2 (en)2007-08-302013-04-23Walter And Eliza Hall Institute Of Medical ResearchDendritic cell marker and uses thereof
ES2566957T3 (en)2007-09-262016-04-18Chugai Seiyaku Kabushiki Kaisha Constant region of modified antibody
EP2050764A1 (en)*2007-10-152009-04-22sanofi-aventisNovel polyvalent bispecific antibody format and uses thereof
EP2271758B1 (en)2008-04-142018-09-12Innovative Targeting Solutions Inc.Sequence diversity generation in immunoglobulins
WO2009143472A2 (en)*2008-05-232009-11-26Aliva Biopharmaceuticals, Inc.Method of generating single vl domain antibodies in transgenic animals
US20100122358A1 (en)2008-06-062010-05-13Crescendo Biologics LimitedH-Chain-only antibodies
KR20110029156A (en)*2008-06-272011-03-22메뤼스 베.페. Antibody Production Non-Human Mammals
LT2346994T (en)2008-09-302022-03-10Ablexis, LlcKnock-in mice for the production of chimeric antibodies
SG172176A1 (en)2008-12-182011-07-28Univ Erasmus Medical CtNon-human transgenic animals expressing humanised antibodies and use therof
EP2394159B1 (en)2009-02-042018-09-26Molecular InnovationsAssays for detecting prorenin, and antibodies used therein
GB0905023D0 (en)2009-03-242009-05-06Univ Erasmus Medical CtBinding molecules
AU2010233993A1 (en)*2009-04-072011-09-08Roche Glycart AgBispecific anti-ErbB-1/anti-c-Met antibodies
PL2975051T3 (en)2009-06-262021-09-20Regeneron Pharmaceuticals, Inc.Readily isolated bispecific antibodies with native immunoglobulin format
PT2564695E (en)2009-07-082015-06-03Kymab LtdAnimal models and therapeutic molecules
US9445581B2 (en)2012-03-282016-09-20Kymab LimitedAnimal models and therapeutic molecules
CN101620635A (en)*2009-08-072010-01-06中兴通讯股份有限公司Page data obtaining method and server, page updating method and server
AU2010328046C1 (en)2009-12-102018-01-18Regeneron Pharmaceuticals, Inc.Mice that make heavy chain antibodies
PT2505654T (en)2010-02-082016-11-18Regeneron Pharma COMMON LIGHT CHAIN MOUSE
US20120021409A1 (en)2010-02-082012-01-26Regeneron Pharmaceuticals, Inc.Common Light Chain Mouse
US20130045492A1 (en)2010-02-082013-02-21Regeneron Pharmaceuticals, Inc.Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20130185821A1 (en)2010-02-082013-07-18Regeneron Pharmaceuticals, Inc.Common Light Chain Mouse
EP3366125A1 (en)*2010-06-172018-08-29Kymab LimitedAnimal models and therapeutic molecules
JP5988969B2 (en)*2010-06-222016-09-07リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Mice expressing a light chain comprising a human λ variable region and a mouse constant region
ES2612459T3 (en)2010-08-022017-05-17Regeneron Pharmaceuticals, Inc. Mice that produce binding proteins that comprise VL domains
WO2012063048A1 (en)2010-11-082012-05-18Kymab LimitedCells & vertebrates for enhanced somatic hypermutation and class switch recombination
HUE024534T2 (en)2011-02-252016-01-28Regeneron Pharma ADAM6 mice
MX342034B (en)2011-02-282016-09-12Hoffmann La RocheMonovalent antigen binding proteins.
US20120310284A1 (en)2011-06-032012-12-06Royal Oak IndustriesPolyaxial pedicle screw
FI3865581T3 (en)2011-08-052024-11-02Regeneron Pharma Humanized universal light chain mice
EP2757875B2 (en)2011-09-192023-03-22Kymab LimitedManipulation of immunoglobulin gene diversity and multi-antibody therapeutics
EP3741862A1 (en)2011-09-192020-11-25Kymab LimitedAnimals, repertoires & methods for the production of human antibodies
WO2013045916A1 (en)2011-09-262013-04-04Kymab LimitedChimaeric surrogate light chains (slc) comprising human vpreb
LT3216871T (en)2011-10-172022-03-25Regeneron Pharmaceuticals, Inc.Restricted immunoglobulin heavy chain mice
GB2496375A (en)2011-10-282013-05-15Kymab LtdA non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en)2011-12-212012-02-01Kymab LtdTransgenic animals
US9253965B2 (en)2012-03-282016-02-09Kymab LimitedAnimal models and therapeutic molecules
BR122021007339B1 (en)2011-12-202022-11-29Regeneron Pharmaceuticals, Inc A METHOD FOR PREPARING A NON-HUMAN ANIMAL, COMPRISING GENETIC MODIFYING AN EX VIVO NON-HUMAN ANIMAL CELL MODIFIED BY PLACING AN ADAM6 GENE, AND, EX VIVO USES OF THE CELL OR TISSUE DERIVED FROM THE NON-HUMAN ANIMAL
RU2770016C2 (en)2012-02-012022-04-14Регенерон Фармасьютикалз, Инк.Humanized rodents which express heavy chains containing vl domains
GB2502127A (en)2012-05-172013-11-20Kymab LtdMultivalent antibodies and in vivo methods for their production
TWI682941B (en)2013-02-012020-01-21美商再生元醫藥公司Antibodies comprising chimeric constant domains
US9788534B2 (en)2013-03-182017-10-17Kymab LimitedAnimal models and therapeutic molecules
KR102186281B1 (en)2013-04-162020-12-03리제너론 파마슈티칼스 인코포레이티드Targeted modification of rat genome
WO2015143414A2 (en)2014-03-212015-09-24Regeneron Pharmaceuticals, Inc.Non-human animals that make single domain binding proteins
HK1231497A1 (en)2014-03-212017-12-22瑞泽恩制药公司Vl antigen binding proteins exhibiting distinct binding characteristics
JP2018508224A (en)2015-03-192018-03-29リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Non-human animals that select light chain variable regions that bind antigen

Also Published As

Publication numberPublication date
IL258338A (en)2018-05-31
US20140130194A1 (en)2014-05-08
CN113150121B9 (en)2024-11-26
JP7110257B2 (en)2022-08-01
IL271804B2 (en)2025-03-01
KR102434557B1 (en)2022-08-23
MX2023001793A (en)2023-03-10
PL2601298T3 (en)2017-03-31
RS55495B1 (en)2017-04-28
JP2021119792A (en)2021-08-19
JP2019047805A (en)2019-03-28
SG10201912639SA (en)2020-02-27
ES2612459T3 (en)2017-05-17
RU2612903C2 (en)2017-03-13
EP3960865A1 (en)2022-03-02
MX363084B (en)2019-03-07
EP2947151A1 (en)2015-11-25
IL271804A (en)2020-02-27
RU2013109068A (en)2014-09-10
AU2011285919A1 (en)2013-02-28
MX2018014787A (en)2023-02-14
JP7078400B2 (en)2022-05-31
HUE031903T2 (en)2017-08-28
CN105753979A (en)2016-07-13
IL271804B1 (en)2024-11-01
EP2601298A1 (en)2013-06-12
KR20210118972A (en)2021-10-01
IL315833A (en)2024-11-01
CN118791596A (en)2024-10-18
MY172618A (en)2019-12-06
DK2601298T3 (en)2017-02-27
HK1181810A1 (en)2013-11-15
CN113150121A (en)2021-07-23
IL258338B (en)2020-01-30
US20120096572A1 (en)2012-04-19
CN103154255B (en)2016-04-06
JP6759303B2 (en)2020-09-23
US9686970B2 (en)2017-06-27
PT2601298T (en)2017-01-09
EP2601298B1 (en)2016-11-30
LT2601298T (en)2017-03-10
CA2807282A1 (en)2012-02-09
US20210163628A1 (en)2021-06-03
US9516868B2 (en)2016-12-13
KR102306967B1 (en)2021-10-01
US20140130193A1 (en)2014-05-08
SMT201700023B (en)2017-03-08
MX2013001360A (en)2013-06-28
JP6146913B2 (en)2017-06-14
KR20200116547A (en)2020-10-12
AU2011285919B2 (en)2015-04-30
RU2017106292A (en)2019-01-21
KR102163138B1 (en)2020-10-08
AU2011285919C1 (en)2015-09-17
CN103154255A (en)2013-06-12
KR20190095511A (en)2019-08-14
CN105753979B (en)2021-05-07
RU2750219C2 (en)2021-06-24
NZ707327A (en)2017-01-27
RU2017106292A3 (en)2020-12-10
SG187673A1 (en)2013-03-28
SMT201700023T1 (en)2017-03-08
IL224523B (en)2018-04-30
US20170226231A1 (en)2017-08-10
JP2018046872A (en)2018-03-29
JP2016054746A (en)2016-04-21
NZ724003A (en)2021-03-26
JP2013535213A (en)2013-09-12
US20220177606A1 (en)2022-06-09
HK1217511A1 (en)2017-01-13
CY1118562T1 (en)2017-07-12
MX345251B (en)2017-01-23
BR112013002695B1 (en)2023-01-24
US20170223939A1 (en)2017-08-10
KR102008655B1 (en)2019-08-08
NZ740900A (en)2023-11-24
US10954310B2 (en)2021-03-23
JP2020078328A (en)2020-05-28
BR112013002695A2 (en)2017-03-01
MX350591B (en)2017-09-11
SI2601298T1 (en)2017-03-31
CN113150121B (en)2024-08-16
WO2012018764A1 (en)2012-02-09
HRP20170322T1 (en)2017-04-21
NZ606824A (en)2015-05-29
KR20130100277A (en)2013-09-10

Similar Documents

PublicationPublication DateTitle
IL271804A (en)Mice that make binding proteins
EP2655415A4 (en)Tri-variable domain binding proteins and uses thereof
IL222980A0 (en)Il-1 binding proteins
EP2555797A4 (en)Tnf- binding proteins
EP2649189A4 (en)Tnf- binding proteins
IL239502B (en)Prolactin receptor binding proteins and uses thereof
ZA201205624B (en)Cd127 binding proteins
IL222749A0 (en)Modified binding proteins inhibiting the vegf-a receptor interaction
ZA201300975B (en)Binding proteins for hepcidin
EP2654792A4 (en)Half immunoglobulin binding proteins and uses thereof
PL2723764T3 (en)Binding domains directed against gpcr: g protein complexes and uses derived thereof
SG2014010334A (en)Fn14 binding proteins and uses thereof
IL226157A0 (en)Antigen binding proteins
GB201003906D0 (en)Binding polypeptides
GB201010143D0 (en)Comb binding
TWM400980U (en)Binding

[8]ページ先頭

©2009-2025 Movatter.jp